| Active Pharmaceutical Ingredients (API) | Fermentation-based APIs primarily for immunosuppressants, oncology, anti-infectives | High entry barriers due to capital-intensive fermentation technology, regulatory certifications, and backward integration | Pharmaceutical manufacturers globally (B2B), including regulated and emerging markets | Specialized fermentation APIs with higher technical complexity | 940 | 78 | Sales of bulk APIs to pharmaceutical companies under long-term contracts | Contract-based sales with negotiated pricing and volume commitments | Innovation in fermentation, regulatory approvals, expanded production capacity, and new API development | Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Sirolimus, Pimecrolimus, Everolimus |
| Formulations | Finished dosage oral solids and injectables across critical care, nephrology, oncology | Backward integration with API business, strong regulatory compliance, and growing brand presence | Healthcare providers and distributors, B2B and B2C markets in India and abroad | Injectables and specialized oral formulations | 260 | 22 | Sales of finished pharmaceutical products directly and via partners in regulated and emerging markets | Direct sales and distribution agreements, multi-tiered pricing | Launch of injectable facility, market expansion in India and US, increasing product portfolio | Tacrocord, Dapute, Mepecon, Gamacon, Obulin |
